MX2024005341A - Dispersion solida amorfa que comprende (s)-1-(1-acriloilpirrolidin -3-il)-3-((3,5-dimetoxifenil)etinil)-5-(metilamino)-1h-pirazol-4- carboxamida. - Google Patents

Dispersion solida amorfa que comprende (s)-1-(1-acriloilpirrolidin -3-il)-3-((3,5-dimetoxifenil)etinil)-5-(metilamino)-1h-pirazol-4- carboxamida.

Info

Publication number
MX2024005341A
MX2024005341A MX2024005341A MX2024005341A MX2024005341A MX 2024005341 A MX2024005341 A MX 2024005341A MX 2024005341 A MX2024005341 A MX 2024005341A MX 2024005341 A MX2024005341 A MX 2024005341A MX 2024005341 A MX2024005341 A MX 2024005341A
Authority
MX
Mexico
Prior art keywords
solid dispersion
amorphous solid
acryloylpyrrolidin
dimethoxyphenyl
ethynyl
Prior art date
Application number
MX2024005341A
Other languages
English (en)
Inventor
Xiangyang Chen
Original Assignee
Beijing Innocare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Innocare Pharma Tech Co Ltd filed Critical Beijing Innocare Pharma Tech Co Ltd
Publication of MX2024005341A publication Critical patent/MX2024005341A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una dispersión sólida amorfa que comprende (S)-1-(1- acriloilpirrolidin-3-il)-3-((3,5-dimetoxif enil)etinil)-5-(metilamino)-1H-pirazol-4-carboxamida (Compuesto I) y un polímero farmacéuticamente aceptable, y una composición farmacéutica que comprende la dispersión sólida amorfa. La dispersión sólida amorfa de la presente invención es estable cuando se almacena y proporciona una mejor solubilidad y biodisponibilidad en comparación con una forma cristalina.
MX2024005341A 2021-11-03 2022-10-28 Dispersion solida amorfa que comprende (s)-1-(1-acriloilpirrolidin -3-il)-3-((3,5-dimetoxifenil)etinil)-5-(metilamino)-1h-pirazol-4- carboxamida. MX2024005341A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163275076P 2021-11-03 2021-11-03
PCT/CN2022/128315 WO2023078179A1 (en) 2021-11-03 2022-10-28 Amorphous solid dispersion comprising (s) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1h-pyrazole-4-carboxamide

Publications (1)

Publication Number Publication Date
MX2024005341A true MX2024005341A (es) 2024-05-20

Family

ID=86240647

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005341A MX2024005341A (es) 2021-11-03 2022-10-28 Dispersion solida amorfa que comprende (s)-1-(1-acriloilpirrolidin -3-il)-3-((3,5-dimetoxifenil)etinil)-5-(metilamino)-1h-pirazol-4- carboxamida.

Country Status (7)

Country Link
EP (1) EP4426293A1 (es)
KR (1) KR20240095240A (es)
CN (1) CN118382437A (es)
AU (1) AU2022381641A1 (es)
CA (1) CA3235435A1 (es)
MX (1) MX2024005341A (es)
WO (1) WO2023078179A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007246895A1 (en) * 2006-05-05 2007-11-15 Astex Therapeutics Limited 4- (2,6-dichloro-benzoylamino) -1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer
CN107840842A (zh) * 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
AU2020232630A1 (en) * 2019-03-04 2021-09-16 Japan Tobacco Inc. Amorphous solid dispersion of pyrazole-amide compound
WO2020208592A1 (en) * 2019-04-12 2020-10-15 Dr. Reddy’S Laboratories Limited Process for preparation of erdafitinib, its purification and amorphous solid dispersion
JP2023509399A (ja) * 2019-12-26 2023-03-08 ベイジン・イノケア・ファーマ・テク・カンパニー・リミテッド （ｓ）－１－（１－アクリロイルピロリジン－３－イル）－３－（（３，５－ジメトキシフェニル）エチニル）－５－（メチルアミノ）－１ｈ－ピラゾール－４－カルボキサミドの結晶形

Also Published As

Publication number Publication date
EP4426293A1 (en) 2024-09-11
WO2023078179A1 (en) 2023-05-11
CA3235435A1 (en) 2023-05-11
KR20240095240A (ko) 2024-06-25
CN118382437A (zh) 2024-07-23
AU2022381641A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
MX2023001311A (es) Agonistas heterociclicos de glp-1.
MX2022009524A (es) Agonistas heterociclicos de glp-1.
BRPI0619868A8 (pt) Dispersão sólida compreendendo um ingrediente ativo tendo um ponto de fusão baixo e comprimido para administração oral compreendendo o mesmo
PE20001493A1 (es) Derivados de acido pirazolcarboxilico, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
DE602005019602D1 (de) Amorphe form einer zimtsäureamidverbindung
PE20121084A1 (es) Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2
CA2406574A1 (en) Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
JO2584B1 (en) Modified Release Formula 1 - ((3-Hydroxyl-Adamant-1-Ylamino) -acetyl) -perrolidine-2 (S) Carbonitrile
WO2003105767A8 (en) ANTIFUNGAL PARENTERAL PRODUCTS
WO2007042468A3 (de) Aerosolformulierung für die inhalation von betaagonisten
MXPA04011914A (es) Formulacion farmaceutica de liberacion modificada.
TW200733884A (en) Emulsifiable concentrate
EP1650206A4 (en) PHENYLAZOLE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND ANTIOXIDANTS
AU5628596A (en) Novel dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof
MX2024005341A (es) Dispersion solida amorfa que comprende (s)-1-(1-acriloilpirrolidin -3-il)-3-((3,5-dimetoxifenil)etinil)-5-(metilamino)-1h-pirazol-4- carboxamida.
TW200735864A (en) Immediate release pharmaceutical formulation
CA2488422A1 (en) Stable solid medicinal ramosetron composition for oral administration
MX2024010346A (es) Compuestos como agonistas de glp-1r.
EP3949967A8 (en) Solid pharmaceutical composition comprising tlr7 agonist
WO2001080641A3 (de) Fungizide wirkstoffkombinationen
MX2022007988A (es) Formas cristalinas de (s)-1-(1-acriloilpirrolidin-3-il)-3-((3,5-di metoxifenil)etinil)-5-(metilamino)-1h-pirazol-4-carboxamida.
WO2009024590A3 (en) Antifungal composition
WO2008122994A3 (en) Stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof
CA2338324A1 (en) Stabilized carvedilol injection solution
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения